TITLE

pharmaceuticals & fine chemicals

PUB. DATE
April 2005
SOURCE
Chemical Week;4/27/2005, Vol. 167 Issue 14, p21
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Presents updates on issues concerning pharmaceutical and fine chemical companies as of April 27, 2005. Information on the licensing of the SimPheny modelling and simulation technology of Genomatica to DSM; Percentage share of Inabata & Co. in Sumitomo Pharmaceuticals that Sumitomo Chemical will acquire; Findings of a study by research and consultancy firm Best Practices regarding the emphasis being placed by pharmaceutical companies on manufacturing.
ACCESSION #
16883439

 

Related Articles

  • Sumitomo Adds Capacity for Antibiotic Bulk Active and Formulation. Scott, Alex // Chemical Week;10/1/2003, Vol. 165 Issue 35, p25 

    Focuses on the completion of the pharmaceutical bulk active pharmaceutical ingredient and drug formulation facilities owned by Sumitomo Chemical and Sumitomo Pharmaceuticals in Oita, Japan. Total cost of the construction; Chemicals to be processed at the facilities; Chemical subsidiaries of the...

  • Scaling up ambitions.  // Chemical Market Reporter;4/19/2004, Vol. 265 Issue 16, Sumitomo Chemical p16 

    Reports on the pharmaceuticals business of Sumitomo Chemical Co. Ltd. conducted through Sumitomo Pharmaceuticals Co. Ltd. Plans of setting up its own development and sales and marketing base in the U.S.; Strategy of licensing products in Europe; Focus of Sumitomo Pharmaceuticals on...

  • Japan build will increase Meropen throughput. Whitfield, Mark // European Chemical News;9/29/2003, Vol. 79 Issue 2070, p24 

    Reports on the completion of the construction of facilities in Oita, Japan by Sumitomo Chemical and Sumitomo Pharmaceuticals in 2003. Use of the facilities; Capital expenditure on the facilities.

  • CRUCELL/DSM SIGN LICENSING PACT WITH MITSUBISHI PHARMA.  // Worldwide Biotech;May2005, Vol. 17 Issue 5, p3 

    Reports on a PER. C6 cell line research license agreement signed by DSM Biologics with Japanese pharmaceutical company Mitsubishi Pharma Corp. in 2005. Benefit of the license agreement for Mitsubishi; Terms of the contract; Information on DSM Biologics.

  • DSM Biologics and Crucell Enter Licensing Deal. Bryner, Michelle // Chemical Week;8/1/2007, Vol. 169 Issue 26, p19 

    The article reports that DSM Biologics and Crucell of Leiden, the Netherlands have entered into an agreement to license a manufacturing technology based on the companies' jointly developed PER.C6 cell line, to LFB Biotechnologies of Paris, France. LFB will use the licensed technology to develop...

  • Pharmaceuticals & fine chemicals.  // Chemical Week;1/1/2003, Vol. 165 Issue 1, p33 

    Presents news briefs on the chemical industry as of January 1, 2003. License deal signed by DSM Biologics with Crucell; Acquisition of the patents of Novozymes relating to the production of a recombinant enzyme for pharmaceutical applications by Solvay.

  • DSM Pharmaceuticals To Double Sterile Manufacturing Capacity. Russel, Ronelle // Pharmaceutical Technology;Feb2003, Vol. 27 Issue 2, p20 

    Reports on Greenville, North Carolina-based drug company DSM Pharmaceuticals' plans to expand its sterile manufacturing capacity. Addition of five freeze dryers and a filling line to its manufacturing site in Greenville; Manufacturing capacity of the facility upon the positioning of freeze...

  • World Briefs.  // Pharmaceutical Technology;Aug2008, Vol. 32 Issue 8, p22 

    The article offers world news briefs related to pharmaceutical industry. In Asia and Pacific, NovaMed Pharmaceuticals (Shanghai) and Pfizer China has formed a partnership in the oncology area in distributing oncology products throughout mainland China. In Europe, an agreement is made between DSM...

  • DSM and Crucell license antibody technology to Sartorius.  // PharmaWatch: Biotechnology;Jul2007, Vol. 6 Issue 7, p16 

    The article reports on the licensing agreement accorded by DSM Biologics and Crucell NV with Sartorius Biotech GmbH. The two companies have agreed to a non-exclusive PER.C6 research licensing deal with Sartorius. In addition, Sartorius will use Crucell's key technology to assess monoclonal...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics